Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet
© Adapala et al; licensee BioMed Central Ltd. 2011
Received: 14 December 2010
Accepted: 28 February 2011
Published: 28 February 2011
Secretory leucocyte protease inhibitor (SLPI) is an anti-inflammatory protein that is constitutively expressed in multiple cell types where it functions to counteract localized tissue inflammation by its anti-inflammatory, antimicrobial and anti-protease properties. Little is known about the expression and implication of SLPI in the regulation of adipose tissue inflammation. Therefore, we tested the hypothesis that obesity induces expression of SLPI in adipose tissue where it functions to counteract adipocyte inflammation.
Male C57BL6 mice were fed a high fat (60% fat calories) or a control diet (10% fat calories) diet for 12 weeks. Adipose tissue expression of SLPI was determined by western blotting and PCR. Fully differentiated adipocytes (3T3-L1) were treated with lipopolysaccharide (LPS, 100 ng/ml) or peptidoglycan (10 μg/ml) for 24 hours in the presence or absence of SLPI. Media was collected for interleukin 6 (IL-6) analysis by enzyme-linked immune absorbent assay (ELISA). RNA was isolated for gene expression analysis by real-time polymerase chain reaction (RT-PCR).
Visceral fat (mesenteric and epididymal) express a higher level of SLPI than subcutaneous fat. The expression of SLPI is mostly in the stromal vascular fraction compared to adipocytes. We also confirmed in vitro that activation of TLR2 and 4 with peptidoglycan and LPS respectively leads to induction of SLPI. Finally, we confirmed that SLPI exerted an anti-inflammatory effect in adipocytes treated with LPS by causing a reduction in expression of IL-6 via a mechanism that included stabilization of cellular IKBα expression.
Our results show that SLPI is also expressed in adipocytes and adipose tissue where it could play an important feedback role in the resolution of inflammation.
Obesity is associated with adipose tissue inflammation that eventually results in insulin resistance. This is characterized by adipose tissue macrophage infiltration [1, 2], elevated expression of inflammatory cytokines, including TNFα , IL6 , monocyte chemoattractant protein (MCP) 1 , plasminogen activator inhibitor (PAI) 1. Inflammatory cytokines produced in adipose tissue act locally and systemically to amplify the inflammatory cascade and oppose insulin signaling in peripheral tissues. However, little is known about mechanisms that lead to resolution of inflammation in adipose tissue. Secretory leucocyte protease inhibitor (SLPI) is a protein that may play a major role in the dampening of inflammation in adipose tissue. It is an 11.7-kD non-glycosylated protein produced primarily at mucosal surfaces, especially in the upper respiratory tract . In the lung , SLPI interacts and inhibits the activity of several proteolytic enzymes, making it an integral component of the defense mechanism in the lung. Apart from its anti-protease activity, SLPI also exerts anti-inflammatory effect against viral and antibacterial targets . SLPI also inhibits NF-κB activation and production of TNF-α and nitric oxide  and SLPI knockout mice have an exaggerated inflammatory response and go into septic shock after LPS administration . Although SLPI is expressed at multiple tissues during inflammation where it acts to counter the inflammatory events, there is no report of adipose tissue expression of SLPI or a potential anti-inflammatory role of SLPI in adipocytes. Therefore, we examined its expression in adipose tissue of mice that have been fed a high fat diet and in 3T3-L1 adipocytes treated with ligands for both toll-like receptors (TLR) 2 and 4, two major inflammatory receptors in adipose tissue [12, 13].
We demonstrate herein, for the first time, that SLPI is upregulated in adipose tissue in obesity. Additionally, we show that SLPI opposes induction of IL6 by LPS in adipocytes. Therefore, SLPI could be a potential target for the regulation of inflammation in adipose tissue.
3T3-L1 Adipocyte Culture
Cells were obtained from ATCC (Manassas, VA) and cultured according to standard conditions. Briefly, cells were grown under 5% CO2 in Dulbecco's Modified Eagles Medium (DMEM) containing 10% fetal bovine serum (Hyclone, Logan, UT) and 0.5% penicillin-streptomycin mixture (Invitrogen, Carlsbad, CA). Cells were allowed to reach confluence, and two days post confluence (day 0), were induced to differentiate with a medium containing 10% fetal bovine serum, 1.7 μM insulin, 1 μM dexamethasone, and 0.5 mM IBMX for 48 h. Thereafter, fresh medium containing only insulin and fetal bovine serum was added for another 2 days. From then on media was replenished every 2 days with DMEM containing only 10% FBS. Fully differentiated cells were treated for 24 hours with either Staphylococcus aureus derived peptidoglycan (10 μg/mL) or E.coli lipopolysaccharride (100 ng/mL) (Sigma, St. Louis. MO).
Eight week old male C57BL/6J mice were fed either a high fat diet (HF, D12492i) with 60% fat calories (n = 8) or a control diet (LF, D12450Bi) with 10% calories (n = 8) from fat (Research Diets, New Brunswick, NJ, http://www.researchdiets.com) for 12 weeks. At the end of the experiment animals were euthanized by CO2 asphyxiation followed by cervical dislocation. All animal care protocols were approved by the Purdue Animal Care and Use Committee. Epididymal adipose tissue was obtained by careful dissection of adipose tissue around the epididymis and used for RNA extraction with Trizol (Invitrogen, Carlsbad, CA) or tissue lysates for western blotting. We also collected subcutaneous (collected from underneath the skin around the lumbar area), mesenteric (collected by careful dissection of adipose tissue from around the intestine) for a comparative analysis of SLPI mRNA expression by real-time PCR. To determine the relative expression of SLPI in adipocytes and stromal vascular fraction (SVF), adipose tissue was subjected to collagenase digestion (1 mg/ml Collagenase type 1, Sigma) in Krebs Ringer Buffer (118.5 mM NaCl, 4.8 mM KCl, 2.7 mM CaCl2, 1.2 mM KH2PO4, 1.1 mM MgSO4, 7H 2O, 25 mM NaHCO3, 5 mM glucose and 5% (w/v) BSA, pH 7.4) with shaking at 150 RPM for 30 minutes at 37°C. After digestion, adipocytes were allowed to separate by flotation and the infranatant solution was centrifuged for 5 minutes at 300 g to pellet the stromovascular fraction (SVF). The adipocyte fraction was washed three times with the KRB buffer to remove contaminants and ensure a pure population of adipocytes. This method has been validated with flow cytometry to yield a 100% pure population of adipocytes. Subsequently, RNA was isolated from adipocytes and the SVF for comparison with whole adipose tissue.
Anti-inflammatory effect of SLPI
Differentiated 3T3-L1 adipocytes were pretreated for 2 hours with 10 ng/ml recombinant human SLPI (R &D Systems, Minneapolis, MN) and then treated with LPS for 3 hours. Media was recovered for ELISA and RNA for RT-PCR.
Real-time quantitative RT-PCR
Total RNA from treated cells was extracted with Trizol Reagent (Invitrogen) according to the manufacturer's protocol. The mRNAs were treated with Turbo DNase (Ambion, Austin, TX) to remove contaminating DNA and reverse transcribed into cDNA using Improm II reverse transcriptase (Promega, Madison, WI). Real-time PCR was performed using a MyIQ real-time PCR detection machine (Bio-Rad) with the Faststart SYBR green based mix (Roche, Indianapolis, IN). Primers sequences used were: IL-6, 5'-AACGATGATGCACTTGCAGA-3' and 5'-GAGCATTGGAAATTGGGGTA-3' for the sense and antisense primers, respectively (14); SLPI, sense, 5'-TGCTTAACCCTCCCAATGTC-3' and antisense, 5'-AATGCTGAGCCAAAAGGAGA-3'; β-actin sense, 5'-ATGGGTCAGAAGGACTCCTACG-3' and antisense, 5'-AGTGGTACGACCAGAGGCATAC-3'; TNFα, 5'-AGCCCCCAGTCTGTATCCTT-3' and 5'-CTCCCTTTGCAGAACTCAGG-3'. Quantification of transcripts was done with the ΔΔ Ct method with normalization against the β-actin.
Whole tissue lysates were obtained by homogenizing tissues and cells in RIPA lysis buffer (0.5 M Tris-HCl, 1.5 M HCl, 2.5% Deoxycholic acid, 10% NP-40 and 10 mM EDTA) supplemented with protease and phosphates inhibitor cocktail (Sigma). Homogenized tissues and cells were then cleared of cellular and tissue debris by centrifugation at 10,000 g for 10 minutes at 4°C. Protein concentrations were determined with the BCA kit (Sigma). For immunoblotting, 50 μg of lysates were resolved on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Membranes were probed with rabbit anti-SLPI (Cat # SC-28803, Santa Cruz, CA, USA) primary antibody and HRP-conjugated anti-rabbit secondary antibody (Cat# 7074, Cell Signaling, Danvers, MA, USA). To determine the role of IKBα protein in the regulation of SLPI effect, the expression of phosphorylated and native IKBα was quantified by western blotting using rabbit primary antibodies (Cat# 2859 and 4812, Cell Signaling, Danvers, MA, USA). Blots were subsequently blotted with the Supersignal® West Pico chemilumniscent reagent (Pierce, Rockford, IL) and exposed to autoradiographic film to capture protein specific signals.
ELISA for Media IL-6
Media concentration of IL-6 was determined with a mouse IL-6 ELISA kit (Endogen, Rockford, IL) according to the manufacturer's instructions. This kit has an assay sensitivity of < 7 pg/ml and an inter assay and intra assay variation of < 10%.
All data were checked for normality and then analyzed using the GLM model analysis. When treatment effects were significant, mean separation was accomplished using the least-squares mean separation procedure.
Adipose tissue expression of SLPI and regulation by high fat diet
Regulation of SLPI expression in adipocytes by inflammatory stimuli and anti-inflammatory effect of SLPI
SLPI stabilized IKBα expression in LPS treated adipocytes
Inflammation plays a major role in obesity-induced insulin resistance by the release of multiple inflammatory cytokines that oppose insulin signaling . Although the endogenous mechanisms that trigger adipose tissue inflammation are not very clear, there is evidence that innate pattern recognition receptors such as TLR2 and 4 play key roles in this process [12, 13]. These innate immune receptors are highly expressed in adipocytes and many functional assays have shown that their activation evokes inflammatory responses that are accompanied by increased expression of many inflammatory mediators (IL6, TNFα, MCP-1) [15, 16]. However, mechanisms that lead to resolution of inflammation in adipose tissue are less well studied; despite the well established paradigm that initiation of inflammatory response is often accompanied by concurrent activation of feedback mechanisms that act to suppress inflammatory response [17–19]. In support of the presence of this mechanism in adipocytes, activation of NFκB and MAPK pathways in adipocytes by LPS is transient and rapidly returns to basal over time . Although several mechanisms are behind the feedback mechanism of inflammation resolution [17–19], SLPI is recognized as a potent anti-inflammatory protein that is induced to suppress tissue inflammation . Therefore, the increase in SLPI expression in adipose tissue in diet-induced obesity suggests that SLPI may play a role to antagonize inflammation in adipose tissue. The higher expression of SLPI in the stromal vascular fraction correlates well with the elevated expression of TNFα. This suggests that SLPI expression is induced in proportion to the degree of inflammation and agrees with a role for SLPI in dampening the inflammatory state. It also indicates that immune cells such as macrophages, which make up the bulk of the stromal vascular fraction may be the major source of adipose tissue SLPI. Therefore, counter-regulatory mechanisms exist in adipose tissue to suppress inflammation and SLPI may be part of these mechanisms. Although SLPI is highly expressed in mucosal surfaces [22, 23], detection of its expression in adipose tissue indicates that it could play a key role in the resolution of inflammation in adipose tissue as well. Indeed, pretreatment of adipocytes with SLPI leads to downregulation of LPS induced IL-6 gene expression and protein secretion, confirming a functional role for SLPI in inflammation resolution in adipocytes. The anti-inflammatory action of SLPI may involve stabilization of IKBα abundance. Activation of TLR2 and 4 increased expression of SLPI in macrophages [10, 24] and in adipocytes as confirmed in this study. Therefore, because TLR2 and TLR4 are activated in adipose tissue in obesity [12, 13], the induction of SLPI in adipose tissue during obesity may be influenced by the activation state of the TLRs. Higher expression of SLPI in the visceral depots (mesenteric and epididymal) than the subcutaneous correlates with greater inflammation in the visceral depots than the subcutaneous depot. Elevated SLPI in the visceral depots could be part of the endogenous anti-inflammatory response to counter localized inflammation in these depots. Because visceral adiposity is linked to insulin resistance, induction of SLPI locally in adipose may also play a role in the prevention of inflammation-induced insulin resistance. In summary, we have demonstrated that obesity is accompanied by increased expression of SLPI in adipose tissue where it may act to suppress local inflammation.
Enzyme linked immunoabsorbent assay
Inhibitor of kappa B
Monocyte chemoattracttant factor
Nuclear factor kappa B
secretory leucocyte protease inhibitor
Tumor necrosis factor.
The authors acknowledge funding for this study from the Department of Animal Sciences, Purdue University.
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.PubMedPubMed CentralView Article
- Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003, 112: 1821-1830.PubMedPubMed CentralView Article
- Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995, 95: 2409-2415. 10.1172/JCI117936.PubMedPubMed CentralView Article
- Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP: Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008, 93: 1931-1938. 10.1210/jc.2007-2191.PubMedView Article
- Ellacott KL, Murphy JG, Marks DL, Cone RD: Obesity-induced inflammation in white adipose tissue is attenuated by loss of melanocortin-3 receptor signaling. Endocrinology. 2007, 148: 6186-6194. 10.1210/en.2007-0699.PubMedView Article
- Caballero AE, Bousquet-Santos K, Robles-Osorio L, Montagnani V, Soodini G, Porramatikul S, Hamdy O, Nobrega AC, Horton ES: Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care. 2008, 31: 576-582. 10.2337/dc07-1540.PubMedView Article
- Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, Brewer MT, Thompson RC, Crystal RG: Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest. 1991, 87: 2207-2215. 10.1172/JCI115255.PubMedPubMed CentralView Article
- Gauthier F, Fryksmark U, Ohlsson K, Bieth JG: Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. Biochim Biophys Acta. 1982, 700: 178-183. 10.1016/0167-4838(82)90095-4.PubMedView Article
- Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM: Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des. 2004, 10: 2891-2905. 10.2174/1381612043383566.PubMedView Article
- Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997, 88: 417-426. 10.1016/S0092-8674(00)81880-2.PubMedView Article
- Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J: Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003, 197: 669-674. 10.1084/jem.20021824.PubMedPubMed CentralView Article
- Himes RW, Smith CW: Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 2010, 24: 731-739. 10.1096/fj.09-141929.PubMedPubMed CentralView Article
- Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA, Saad MJ: Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007, 56: 1986-1998. 10.2337/db06-1595.PubMedView Article
- Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A, Taskinen MR: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003, 166: 387-394. 10.1016/S0021-9150(02)00371-4.PubMedView Article
- Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006, 116: 3015-3025. 10.1172/JCI28898.PubMedPubMed CentralView Article
- Briscoe CP, Looper D, Tran P, Herrera J, McDonnell SR, Bhat BG: LPS-induced biomarkers in mice: a potential model for identifying insulin sensitizers. Biochem Biophys Res Commun. 2007, 361: 140-145. 10.1016/j.bbrc.2007.06.164.PubMedView Article
- Ashino T, Yamanaka R, Yamamoto M, Shimokawa H, Sekikawa K, Iwakura Y, Shioda Numazawa SS, Yoshida T: Negative feedback regulation of lipopolysaccharide-induced inducible nitric oxide synthase gene expression by heme oxygenase-1 induction in macrophages. Mol Immunol. 2008, 45: 2106-2115. 10.1016/j.molimm.2007.10.011.PubMedView Article
- Baetz A, Frey M, Heeg K, Dalpke AH: Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem. 2004, 279: 54708-54715. 10.1074/jbc.M410992200.PubMedView Article
- Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G: TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007, 131: 1124-1136. 10.1016/j.cell.2007.10.034.PubMedView Article
- Chung S, Lapoint K, Martinez , Kennedy A, Boysen Sandberg M, McIntosh MK: Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006, 147: 5340-5351. 10.1210/en.2006-0536.PubMedView Article
- Ward PA, Lentsch AB: Endogenous regulation of the acute inflammatory response. Mol Cell Biochem. 2002, 234-235: 225-228. 10.1023/A:1015944709177.PubMedView Article
- Nyström M, Westin UP, Linder C, Ohlsson K: Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa. Mediators Inflamm. 2001, 10: 269-272.PubMedPubMed CentralView Article
- Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung CellMol Physiol. 2001, 280: L79-87.
- Jin F, Nathan CF, Radzioch D, Ding A: Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 1998, 66: 2447-2452.PubMedPubMed Central
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.